cutoff time point based on PK? [NCA / SHAM]

posted by Biostats – India, 2017-11-26 07:36  – Posting: # 18006
Views: 1,658

Dear Sir,

Thanks for your prompt response

As per Methylphenidate FDA draft guidance cut-off time point should be Average of Tmax + 2*SD (Average and SD should be calculated from IR portion).

Can we apply this method for EMA submission?

Can we apply reference-scaling for all seven pk parameters or only for pk parameters from first phase i.e. Cmax(1) & AUC(1) as expected large intra-subject variability in first phase?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

Activity
 Admin contact
20,128 posts in 4,245 threads, 1,383 registered users;
online 7 (2 registered, 5 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 09:40 CET

You really don’t know what you don’t know until you write about it.
Then, everyone knows what you don’t know.    Rod Machado

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5